Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients
NCT03776123 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 347
Last updated 2024-05-29
Summary
The objective of this Post Marketing Surveillance (PMS) is to collect and describe safety and effectiveness profile of Cabometyx™ in real clinical practice setting, according to the approved labelling after the approval of marketing authorization.
Conditions
- Renal Cell Carcinoma
- Hepatocellular Carcinoma
- Differentiated Thyroid Carcinoma
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Ipsen Medical Director · Ipsen
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-05-15
- Primary Completion
- 2024-03-26
- Completion
- 2024-03-26
Countries
- South Korea
Study Locations
More Related Trials
-
Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy
NCT07151326 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer
NCT04401709 ·Status: UNKNOWN ·Phase: PHASE3
-
A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.
NCT05987358 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma
NCT01717066 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
NCT06911255 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma
NCT01556815 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Folfox4 Chemotherapy Regimen to Prevent Early Postoperative Recurrence for HCC-PVTT Patients
NCT02813096 ·Status: UNKNOWN ·Phase: NA
-
Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.
NCT05620498 ·Status: UNKNOWN ·Phase: PHASE2
-
The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients
NCT03511703 ·Status: UNKNOWN ·Phase: PHASE2
-
The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma
NCT03652467 ·Status: UNKNOWN ·Phase: PHASE1
-
Photodynamic Therapy in Locally Advanced Hilar Cholangiocarcinoma
NCT02725073 ·Status: UNKNOWN ·Phase: PHASE2
-
Biomarker Discovery in Patients With Advanced Biliary Tract Cancer
NCT04871321 ·Status: COMPLETED
-
Antiviral Therapy for Patients With Liver Cancer After Surgery
NCT05466565 ·Status: RECRUITING
-
A Study of PTX-9908 Injection for Non-resectable HCC with TACE
NCT03812874 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Observation Study: Superselective Drug-Eluting Chemoembolization in Unresectable Intermediate and Advanced HCC Patients
NCT03273608 ·Status: UNKNOWN
-
Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC
NCT02650271 ·Status: COMPLETED ·Phase: PHASE3
-
Cabozantinib in Hepatocellular Carcinoma
NCT04588051 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study on Effectiveness and Safety of Hepatocellular Carcinoma Patients Treated With CyberKnife
NCT02363218 ·Status: UNKNOWN ·Phase: PHASE2
-
Effects of Antiviral Therapy on Patients With HBV-related HCC
NCT05406089 ·Status: COMPLETED
-
Survival According to the Feeding Artery Obliteration by Chemoembolization for Unresectable Hepatocellular Carcinoma
NCT01677468 ·Status: UNKNOWN ·Phase: NA
-
A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
NCT04856761 ·Status: UNKNOWN
-
TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors
NCT06487663 ·Status: RECRUITING ·Phase: NA
-
Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer
NCT05156788 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
NCT03941873 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
NCT01908426 ·Status: COMPLETED ·Phase: PHASE3